The National Institute of Allergy and Infectious Diseases announced Monday that it has initiated a phase 1 clinical trial of three experimental messenger RNA HIV vaccines.
The study will be conducted by NIAID-funded HIV Vaccine Trials Network (HVTN), which is based at the Fred Hutchinson Cancer Research Center in Seattle.
“Finding an HIV vaccine has proven to be a daunting scientific challenge,” NIAID Director Anthony S. Fauci, MD, said in a press release. “With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to learn whether mRNA